Conflict of interest: The authors declare no conflict of interest.
Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia
Article first published online: 11 JUN 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 10, pages 1761–1766, October 2014
How to Cite
Zhang, L., Cao, Z., Ruan, M., Zeng, Q., Zhao, L., Li, Q., Zou, Y., Wang, J. and Zhu, X. (2014), Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia. Pediatr. Blood Cancer, 61: 1761–1766. doi: 10.1002/pbc.25109
- Issue published online: 19 AUG 2014
- Article first published online: 11 JUN 2014
- Manuscript Accepted: 23 APR 2014
- Manuscript Received: 19 DEC 2013
- Tianjin Science and Technology Support Plan. Grant Number: 12ZCDZSY18100
- Ministry of Science and Technology Major Projects. Grant Number: 2011ZX09302-007
- Youth Scientific Research Funds of Peking Union Medical College. Grant Number: 2012J17
- Natural Science Fund Foundation Project. Grant Number: 81200396
- polymerase chain reaction
To determine the prognostic significance of the detection of the minimal residual disease (MRD) in children with AML1/ETO AML, we compared the results of reverse-transcription polymerase chain reaction (RT-PCR) and quantitative reverse-transcription polymerase chain reaction (RQ-PCR).
Between January 2006 and February 2013, 70 patients (≤16 years of age) with AML1/ETO AML were included in our study. Bone marrow samples were evaluated using by both RT-PCR and RQ-PCR assays. AML1/ETO transcripts were normalized to 105 ABL copies.
When treated with fewer than four courses of therapy, no association was found between positive RT-PCR results and relapse. After four courses of therapy, a positive RT-PCR result was correlated with a probability of relapse. After induction chemotherapy, a >1.8 log reduction in AML1/ETO transcripts in BM determined by RQ-PCR may represent a subgroup of patients at low risk for relapse. MRD levels after consolidation (Courses 2 and 3) were also informative.
Both RT-PCR and RQ-PCR can be used to detect MRD in childhood AML1/ETO AML. RQ-PCR can identify patients who are at high risk of relapse earlier than can RT-PCR. Pediatr Blood Cancer 2014; 61:1761–1766. © 2014 Wiley Periodicals, Inc.